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Zusammenfassung
Trastuzumab (Herceptin) ist der erste humanisierte
monoklonale Antikörper zur Behandlung des Mamma-
karzinoms. Er ist gegen den humanen epidermalen
Wachstumsfaktor-Rezeptor-2 (HER2/neu) gerichtet, der
bei 25–30% aller humanen Mammakarzinome überexpri-
miert ist. Nach erfolgreichen Phase-I-/II-Studien folgten
mehrere Phase-III-Studien mit Einsatz von Trastuzumab
alleine oder in Kombination mit unterschiedlichen Che-
motherapien. Trastuzumab ist für Patientinnen indiziert,
deren Tumor in einem validierten immunhistochemi-
schen Test eine HER2/neu-Überexpression (3+) und/oder
Genamplifikation (Fluoreszenz-in-situ-Hybridisierung)
aufweist. Unter Berücksichtigung von Wirksamkeit und
Nebenwirkungsprofil zeigte die Kombinationstherapie
von Trastuzumab und Paclitaxel erstmals in der Ge-
schichte der palliativen Therapie des Mammakarzinoms
eine Verbesserung aller klinischen Parameter, einschließ-
lich des Gesamtüberlebens. Mittlerweile ist der Einsatz
von Trastuzumab ein etablierter Bestandteil der System-
therapie beim metastasierten Mammakarzinom und soll-
te seit der exzellenten Datenlage zur adjuvanten Situa-
tion (NSABP-B31, NCCTG-N9831, HERA) mit signifikant
besserem rezidiv- und metastasenfreiem Überleben für
die Therapiearme mit Trastuzumab hier zum Einsatz
kommen. Derzeit laufende Studien untersuchen die Wirk-
samkeit einer Kombinationstherapie mit Trastuzumab in
der neoadjuvanten Situation. Trastuzumab gilt nach ak-
tueller Datenlage als gut verträgliche Substanz. Die wich-
tigste Nebenwirkung ist die Ausbildung einer Herzinsuffi-
zienz, weshalb sich die Empfehlung einer basalen kardia-
len Diagnostik vor Therapiestart sowie unter und nach
der Therapie ergibt.
Key Words
Herceptin · Trastuzumab · Monoclonal antibody, 
humanized · HER2/neu
Summary
Trastuzumab (Herceptin) is a humanized monoclonal
antibody that specifically targets HER2/neu (human epi-
dermal growth factor receptor-2) breast cancer cells,
which are overexpressed in about 25–30% of breast car-
cinomas. After phase I and II trials, several phase III
studies of trastuzumab alone or in combination with var-
ious chemotherapies were conducted. Patients with
HER2/neu overexpression levels of 3+ determined by
immunohistochemical assay or gene amplification (fluo-
rescence in situ hybridization) derive most clinical bene-
fit from trastuzumab. Taking into consideration efficacy
and side effect profile, the combination of trastuzumab
and paclitaxel showed an improvement of all clinical pa-
rameters, including overall survival, for the first time in
the history of palliative breast cancer therapy. The appli-
cation of trastuzumab has meanwhile become an estab-
lished part of systemic therapy of metastastic breast
cancer, and excellent data of its application in the adju-
vant setting now exist (NSABP-B31, NCCTG-N9831,
HERA), with significantly better relapse-free survival in
the treatment arms with trastuzumab. Ongoing trials
investigate the role of trastuzumab in the neoadjuvant
setting. Trastuzumab is generally well tolerated. Car-
diotoxicity is the main concern, thus monitoring of
cardiac function is recommended.
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Introduction
HER2 (human epidermal growth factor receptor-2) is a trans-
membrane tyrosine kinase receptor belonging to the family of
epidermal growth factor receptors. It is encoded by the
HER2/neu proto-oncogene located on chromosome 17 q 21
[1]. HER2 is overexpressed in approximately 25–30% of all
breast cancers [2]. HER2 overexpression stimulates cancer
cell growth and correlates with a shorter relapse-free interval
and overall survival time [3]. The unfavorable prognosis asso-
ciated with HER2 overexpression has been confirmed by nu-
merous studies [4]. HER2 overexpression is determined im-
munohistochemically. Currently, the HercepTest® (Dako,
Glostrup, Denmark) using a polyclonal antibody against
HER2/neu is the most commonly used test. A HER2 score of
0 and 1+ is classified as negative, a HER2 score of 3+ as clear-
ly positive. In the case of a HER2 score of 2+ (marginally pos-
itive), fluorescence in situ hybridization (FISH) should follow.
Accurate determination of HER2 status is an indispensable
prerequisite to every trastuzumab treatment.
Therapy of HER2-Overexpressing Breast Cancer with
Trastuzumab
Beside surgery, radiation, chemotherapy and antihormonal
therapy, immunotherapy is a promising new approach in
breast cancer treatment. Trastuzumab (Herceptin, Hoffman-
La Roche, Grenzach-Whylen, Germany) was the first anti-
body approved for breast cancer therapy by the FDA (U.S.
Food and Drug Administration). Trastuzumab is a murine
monoclonal antibody that targets the extracellular domain of
the HER2 protein. The exact mechanism of its anticancer ac-
tivity is not yet fully understood, and several different ways of
action have been suggested. The response to therapy corre-
lates with HER2 overexpression. Cells with normal receptor
levels are not efficiently inhibited. Trastuzumab is clearly indi-
cated in patients with immunohistochemical scores of 3+ or, if
the score is 2+, with amplification detected by FISH analysis.
In the USA, trastuzumab was approved for the treatment of
metastatic breast cancer in 1998, and European approval fol-
lowed in 2000. Phase II and III studies demonstrated efficacy
and tolerability of trastuzumab in metastatic breast cancer pa-
tients with HER2 overexpression. Trastuzumab has demon-
strated antitumor effects when administered as a single agent
and additive and synergistic effects when given in combina-
tion with other antineoplastic agents or hormonal therapy.
Studies examining the effects of a combination of trastuzumab
and chemotherapeutic agents on tumor growth in tissue cul-
ture and xenograft models demonstrated synergy between
trastuzumab and cisplatin/carboplatin, vinorelbine, thiotepa,
gemcitabine at low concentrations and etoposide, and additiv-
ity between trastuzumab and doxorubicin, epirubicin, pacli-
taxel, docetaxel, vinblastin and methotrexate. In vitro fluo-
rouracil was found to have antagonistic interaction with
trastuzumab [5]. At standard doses of 4 mg/kg loading dose
followed by 2 mg/kg weekly, the mean half-life is approxi-
mately 28.5 days (95% confidence interval (CI) 25.5–32.8
days) with a washout period of up to 20 weeks (95% CI 18–24
weeks). The steady-state concentration is reached at approxi-
mately 20 weeks (95% CI 18–24 weeks). Weekly intravenous
infusions of trastuzumab show a volume of distribution which
approximates the serum volume (2.95 l). The recommended
initial loading dose of trastuzumab is 4 mg/kg administered via
intravenous infusion over 90 min, followed by a weekly dose
of 2 mg/kg given over 30 min. Three-weekly intervals with 
8 mg/kg loading dose followed by 6 mg/kg treatment dose are
also being used. In 2 phase II trials (BO15935, WO16229), pa-
tients were treated with a loading dose of 8 mg/kg trastuzu-
mab administered as a 90-min intravenous infusion followed
by doses of 6 mg/kg every 3 weeks (q3w). The q3w regimen
was well tolerated, with safety profiles similar to that of stan-
dard weekly regimen [6]. No formal drug interaction studies
were performed. According to the population pharmakokinet-
ic analysis by Genentech (San Francisco, CA, USA), adminis-
tration of concomitant drugs (anthracycline/cyclophospha-
mide or paclitaxel) does not appear to influence the pharma-
kokinetics.
Serum levels of the circulating HER2/neu shed antigen can be
measured by enzyme-linked immunosorbent assays (ELISA).
At the moment the serum level testing has to be seen as a
complementary method rather than an alternative to HER2/
neu tissue analysis. Due to only minimal penetration into cere-
brospinal fluid, trastuzumab is not suitable for treatment of
cerebral metastases [7].
Trastuzumab in the Metastatic Situation
Trastuzumab is applied without interruption at least until ap-
pearance of relevant cardiac toxicity or disease progression.
Clinical data of the retrospective admission study show a ben-
efit for patients with progressive disease under trastuzumab
treated further on with trastuzumab. The encouraging results
of preliminary clinical trials [8] were followed by initiation of
major pivotal trials using chemotherapy +/– trastuzumab and
trastuzumab as monotherapy in metastatic breast cancer. Effi-
cacy and safety data of these trials led to the FDA approval of
trastuzumab in metastatic HER2/neu-overexpressing breast
cancer.
Trastuzumab Monotherapy
Cobleigh et al. [9] treated 222 metastatic breast cancer pa-
tients with weekly trastuzumab as second- or third-line thera-
py. 68% of them had previously received chemotherapy
(H0649g). The overall response rate was 15% with a median
Breast Care 2006;1:78–84Herceptin: State of the Art 79
time to progression of 9.1 months and a median survival of 
13 months. There were 8 complete and 26 partial remissions.
Of all patients, 40% suffered mild toxicity. Cardiac side effects
were observed in 4.7% (10 patients) of which 9 were pretreat-
ed with doxorubicin. Vogel et al. [10] treated 114 metastatic
breast cancer patients with 2 different dosages of first-line
trastuzumab (H0650g). One group received a loading dose of
8 mg/kg and 4 mg/kg maintenance dose, the other group 
4 mg/kg followed by 2 mg/kg. Treatment was well tolerated in
both groups. Toxicity was more pronounced in the dose-inten-
sified group but generally mild. The overall response rate was
26% (95% CI 18–34%) without a significant difference be-
tween the groups (standard dose 24%, dose intensified 28%).
Subgroup analysis demonstrated an elevated response rate in
immunohistochemistry (IHC) 3+ (35%) and FISH-positive
patients (41%). The median survival was 24.4 months, approx-
imating the survival rate in the pilot phase III combination
study (25 months).
Trastuzumab in Combination Therapies
In Germany, trastuzumab is approved in combination with pa-
clitaxel or docetaxel as a first-line regimen. First results of a
treatment combining paclitaxel (90 mg/m2 q1w) and trastu-
zumab were published in 1999. The response rate was 61%
[11]. Slamon et al. [12] compared the treatment effects of
chemotherapy alone versus chemotherapy and weekly
trastuzumab combined in a cohort of 469 patients with HER2-
overexpressing tumors and without previous treatment for
metastatic breast cancer (H0648g). Patients were randomized
to one of 4 treatment regimens based on the presence or 
absence of prior anthracycline adjuvant therapy: trastuzu-
mab plus anthracycline (doxorubicin 60 mg/m2 or epirubicin
75 mg/m2) and cyclophosphamide (6 × 60/600 mg/m2 q3w),
versus anthracycline and cyclophosphamide alone (in the case
of no prior anthracyclines), or trastuzumab plus paclitaxel 
(6 × 175 mg/m2 q3w) versus paclitaxel alone. The trial demon-
strated favorable effects of trastuzumab on response rate, me-
dian time to disease progression, median duration of response
and survival. Overall response rates of chemotherapy plus
trastuzumab versus chemotheray alone were 50% and 32% 
(p < 0.001). The combination therapy with anthracycline
chemotherapy plus trastuzumab showed an increased re-
sponse rate of 56% versus 42% for the same chemotherapy
regimen without trastuzumab (p = 0.02). Response rates to
trastuzumab plus paclitaxel versus paclitaxel alone were 41%
and 17%, respectively (p < 0.001). Both trastuzumab groups
showed an improved time to disease progression compared to
groups receiving chemotherapy alone. Time to disease pro-
gression was 7.8 months for anthracycline/cyclophosphamide
plus trastuzumab versus 6.1 months for anthrazycline/
cyclophosphamide alone (p < 0.001) and 6.9 months for pacli-
taxel plus trastuzumab versus 3.0 months for paclitaxel alone
(p < 0.001). The median duration of response in all 469 pa-
tients was 9.1 months with trastuzumab versus 6.1 months
without trastuzumab (p < 0.001). Trastuzumab improved the
median survival time by 4.8 months compared to chemothera-
py alone (p = 0.046). Symptomatic and asymptomatic cardiac
dysfunction was observed in 63 patients. NYHA (New York
Heart Association) class III or IV dysfunction was developed
by 16% of patients treated with anthracycline/cyclophos-
phamide and trastuzumab, 3% of patients treated with anthra-
cycline/cyclophosphamide alone, 2% of patients treated with
paclitaxel and trastuzumab and 1% of patients treated with
trastuzumab alone.
The efficacy and safety of the combination of trastuzumab and
taxanes was confirmed by another current phase III trial.
First-line trastuzumab plus docetaxel compared with doce-
taxel alone was investigated in 188 patients who had IHC 3+
and/or FISH+ disease (M77001). Weekly trastuzumab was ad-
ministered until progression. Docetaxel was given at a dose of
6 × 100 mg/m2 q3w. The addition of trastuzumab to docetaxel
improved all clinical outcomes, compared with docetaxel
alone: overall response rate (61 vs. 34%, p = 0.0002), median
duration of response (11.4 vs. 5.1 months, p = 0.0011), median
time to disease progression (10.6 vs. 5.7 months, p = 0.0001)
and median survival (30.5 vs. 22.1 months, p = 0.0062). Median
survival was prolonged in patients who received trastuzumab
concomitantly with docetaxel (30.5 months) compared with
those who received trastuzumab after progressing on doce-
taxel (24.5 months; 48% of patients crossed over) and those
who received docetaxel alone (19.1 months) [13].
In the pivotal trial, the combination of trastuzumab with an-
thracyclines was associated with a higher incidence of car-
diotoxicity which is why this regimen was not approved by the
FDA. In the first part of phase II, 26 HER2-positive patients
were treated with epirubicin and cyclophosphamide (EC) 
4 × 60/600 mg/m2 q3w (EC60) plus trastuzumab every week
until week 103. The overall response rate was 71%. In the sec-
ond part of phase II, 25 HER2-positive patients were treated
with an elevated EC dose of 4 × 90/600 mg/m2 q3w (EC90)
and weekly trastuzumab for 103 weeks. 25 HER2-negative pa-
tients were treated with EC90. Cardiac function was closely
monitored. 2 EC90 plus trastuzumab-treated patients experi-
enced symptomatic congestive heart failure, and 1 EC60 plus
trastuzumab-treated patient experienced an asymptomatic 
decrease in left ventricular ejection fraction (LVEF) to < 50%.
Objective response rates with EC60 plus trastuzumab and
EC90 plus trastuzumab were 62% and 64%, respectively and
26% for EC90 alone [14]. In the following phase III study
(M77003), 100 HER2-positive patients were treated with
EC 90/600 mg/m2 q3w followed by trastuzumab. As control
group, 100 HER2/neu-negative patients were treated with EC
90/600 mg/m2 q3w without trastuzumab. Liposomal doxoru-
bicin formulations provided an advantage over conventional
doxorubicin in terms of cardiac safety [15]. One trial reported
the use of liposomal doxorubicin in combination with trastu-
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zumab. The overall response rate in 33 evaluable patients 
was 58%.
In combination therapies with trastuzumab and navelbine, 
40 HER2-positive patients with metastatic disease (82% with
prior chemotherapy) showed an overall response rate of 75%.
The combination therapy was well tolerated. The most com-
mon hematological side effect was neutropenia. 3 patients de-
veloped grade II cardiotoxicity. Two confirmatory multicenter
trials using the same treatment regimen as first-line therapy
demonstrated a similar degree of activity [16]. Further combi-
nation therapies of trastuzumab and capecitabine, gem-
citabine and platinum salts presently demonstrate few impres-
sive results because of small patient cohorts and short obser-
vation periods [17–19]. Table 1 shows recommendations for
trastuzumab therapy in combination with chemotherapy. 
Future and ongoing studies will provide further data on the
therapeutic efficacy.
Trastuzumab and Anti-Hormonal Therapy
There is evidence for interaction or ‘cross talk’ between
HER2/neu and estrogen receptor (ER) signaling pathways in
breast cancer. According to the results of several studies,
HER2/neu overexpression is associated with resistance to
anti-hormonal therapy [20]. The International Breast Cancer
Study Group analyzed the data of 1,506 patients and found a
correlation of HER2 overexpression and negative hormone
receptor (HR) status. Borg et al. [21] and Ravdin et al. [22] re-
ported a decreased effect of tamoxifen in HR-positive and
HER2-overexpressing patients. To investigate the relationship
of HER2 overexpression and HR expression, HER2, ER and
progesterone receptor (PR) were examined as continuous
variables in 1,359 breast cancer specimens in 14 cell lines some
of which had been transfected with the HER2/neu gene.
Transfected cell lines expressed significantly lower levels of
ER and PR than parental lines. In 2 clinical cohorts, primary
tumors with HER2 overexpression or pathologic amplifica-
tion in the nucleus had significantly lower levels of ER and
PR than patients without HER2 overexpression or amplifica-
tion. Therefore, pathologic HER2 amplification and overex-
pression seems to downregulate expression of ER and PR,
thus impairing the efficacy of hormone therapy. Results of a
neoadjuvant study comparing letrozole versus tamoxifen in
ER-positive and/or PR-positive postmenopausal primary
breast cancer patients – having shown a good response in ER-
positive, HER2/neu-positive cancers and infrequent responses
to tamoxifen – indicate that the response in HER2/neu-posi-
tive tumors to aromatase inhibitors, such as letrozole, may dif-
fer from that seen with tamoxifen [23]. A decreased effect of
tamoxifen in HR-positive and HER2/neu-overexpressing pa-
tients was demonstrated [21]. A potential mechanism is the
observed downregulation of ER and PR in HER2/neu-over-
expressing tumor cells [24]. Thus, it has been suggested that
combining hormonal agents with trastuzumab may be a
rational approach for clinical trials. A phase III randomized,
controlled, open label trial of anastrozol with or without
trastuzumab is being conducted in 202 HR-positive, HER2/
neu-positive metastatic breast cancer patients. Moreover,
there are several ongoing trials with letrozole +/– trastuzumab.
The largest is enrolling 300 patients and will investigate letro-
zole with or without trastuzumab as first-line therapy in
metastatic breast cancer.
Trastuzumab in the Adjuvant and Neoadjuvant 
Situation
The efficacy of trastuzumab plus chemotherapy in patients
with HER2/neu-positive metastatic breast cancer generated
interest in the use of trastuzumab in the adjuvant situation.
After a pilot study of 40 stage II and III breast cancer patients,
several multicenter, randomized, adjuvant trials were initiat-
ed, each with a cardiac monitoring plan:
1. The NSABP (National Surgical Adjuvant Breast and Bowel
Project) trial B-31 uses anthracycline/cyclophosphamide q3w
(4 cycles), followed by paclitaxel plus trastuzumab q3w (4 cy-
cles) versus the same chemotherapy regimen without
trastuzumab in node-positive, HER2-positive breast cancer
patients.
2. The NCCTG (North Central Cancer Treatment Group) In-
tergroup trial N9831 is a randomized 3-arm trial. Treatment
with anthracycline/cyclophosphamide q3w (4 cycles) in all 
3 arms is followed by weekly paclitaxel (12 cycles) versus
weekly paclitaxel (12 cycles) plus trastuzumab for 1 year ver-
sus weekly paclitaxel and trastuzumab (12 cycles) followed 
by trastuzumab monotherapy (40 cycles). Recruited patients
have node-positive or high-risk node-negative breast cancer
overexpressing HER2.
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Table 1. Recommendations for trastuzumab therapy in metastatic breast
cancer
Combination Oxford AGO 

LOE  GR  
Paclitaxel 1b A ++ 
Docetaxel 1b A ++ 
Paclitaxel/carboplatin 1b A ++ 
Vinorelbine 2b C + 
Docetaxel/platinum complex 2b C +/– 
Epirubicin/cyclophosphamide 2b C +/– 
PEG-liposomal doxorubicin 2b C +/– 
Capecitabine 2b C +/– 
Gemcitabine 2b C +/– 
LOE = Levels of evidence, GR = grade of recommendation, 
AGO = Arbeitsgemeinschaft Gynäkologische Onkologie. 
The Intergroup NCCTG N9831 and the NSABP B-31 trastu-
zumab adjuvant trials have presented combined data of a 
first interim analysis based on 395 events of 3151 treated 
patients with a median follow-up of 2.4 years on B-31 and 
1.5 years on N9831. Trastuzumab administered simultaneously
with paclitaxel following doxorubicin/cyclophosphamide re-
duced the risk of recurrence by 52% compared to controls
(stratified log rank p-value = 3 × 10–12, stratified HR (95% CI)
0.48 (0.39–0.60)). The absolute difference in disease-free sur-
vival was 12% after 3 years and 18% after 4 years. The relative
risk reduction benefit was present in all analyzed subgroups
(age, HR status, tumor size, number of positive nodes). There
was no statistical power to establish efficacy in the node-nega-
tive subset, as NSABP B-31 only included node-positive pa-
tients, and NCCTG N9831 only enrolled 13% of high-risk
node-negative patients in the control and 11% in the investi-
gational arm. As for the secondary efficacy endpoint, overall
survival, the addition of trastuzumab showed a significant sur-
vival advantage with a relative risk reduction of 33% at a me-
dian follow-up of 2 years (stratified log rank p-value = 0.015,
stratified HR (95% CI) 0.67 (0.48–0.93)). The absolute differ-
ence in time to first distant recurrence was 9% after 3 years
and 16% after 4 years [25]. The NCCTG N9831 trial further
evaluates the trastuzumab schedule given sequential to or
concurrent with paclitaxel, each showing a decreased recur-
rence compared with controls. At the interim comparison, the
concurrent versus sequential treatment led to a 36% decrease
in recurrence (stratified log rank p-value = 0.0114, stratified
HR (95% CI) 0.64 (0.46–0.91)) [26]. In the interim analysis of
the NSABP B-31 trial, the incidence of cardiac events was
4.0% in the trastuzumab-containing regime versus 0.6% with-
out trastuzumab. In the investigational group (n = 846), 
30 cases of congestive heart failure (CHF) and no cardiac
deaths were observed, compared with the control group 
(n = 811) where 3 CHFs and 1 cardiac death occurred [25]. In
the NCCTG N9831, there was 0% incidence of cardiotoxicity
in the control, 2.2% in the sequential and 3.3% in the concur-
rent arm [25].
3. In the BCIRG (Breast Cancer International Research
Group) phase III randomized trial 006, patients with node-
positive or high-risk node-negative, HER-2-overexpressing
primary breast cancer are randomized to one of 3 treatment
arms: After 4 cycles of doxorubicin/cyclophosphamide (A/C)
q3w, patients receive either 4 cycles of docetaxel q3w, or 4 cy-
cles of docetaxel q3w plus trastuzumab for 1 year, or doce-
taxel plus carboplatin (6 cycles) followed by trastuzumab for 
1 year. A total of 3,222 patients were recruited. After a medi-
an follow-up of 23 months, the 2 trastuzumab-containing arms
reached the disease-free survival endpoint: HR of 0.49 with
AC followed by docetaxel and trastuzumab and 0.61 with
docetaxel, carboplatin and trastuzumab compared to AC fol-
lowed by docetaxel [26].
4. The HERA (Herceptin Adjuvant Trial) study is a world-
wide multicenter study in which patients with verified HER2
overexpression are randomly assigned to 3 different treatment
groups: i) trastuzumab 1 year q3w after optimal primary ther-
apy, ii) trastuzumab 2 years q3w after optimal primary thera-
py, iii) optimal primary therapy only (surgery, radiotherapy,
endocrine therapy).
The results of the US-based studies are supported by the in-
terim analysis of this adjuvant trastuzumab international
HERA trial at the 1-year median follow-up. Trastuzumab
given for 1 year following adjuvant chemotherapy significantly
prolonged the 2-year disease-free survival (p-value < 0.0001,
HR (95% CI) 0.54 (0.43–0.67)) independent of patient base-
line characteristics and including node-negative patients. The
addition of trastuzumab also showed a significant prolonga-
tion of secondary efficacy endpoints, relapse-free survival
(RFS) and distant disease-free survival (DDFS). For RFS, the
2-year outcome was 78.6 vs. 87.2% and for DDFS 81.8 vs.
89.7%. At the 1-year follow-up, the secondary endpoint of
overall survival had not yet been reached. The interim analysis
did not include a comparison of 12 months versus 24 months
of trastuzumab treatment [27]. The incidence of cardiac events
defined as decrease by ≥ 10 EF points and LVEF < 50% were
2.2% in the control group (n = 1736) versus 7.1% in the 1-year
trastuzumab group (n = 1677) of the HERA trial. The men-
tioned LVEF criteria and a symptomatic CHF NYHA class
III/IV was seen in 0 vs. 0.5% [28].
Buzdar et al. [28] investigated the role of trastuzumab in the
neoadjuvant setting of HER2/neu-positive breast cancer. In
this trial, 42 patients were randomized to a primary systemic
therapy with either 4 cycles of paclitaxel (225 mg/m2 q3w) 
followed by 4 cycles of FEC (fluorouracil 500 mg/m2 days 
1 and 4, epirubicin 75 mg/m2 day 1 and cyclophosphamide 
500 mg/m2 day 1 q3w) or the same regimen in combination
with trastuzumab (2 mg/kg weekly × 12). The addition of
trastuzumab increased the pathologic complete response from
26.3% (n = 19) to 65.2% (n = 23). Our group [29] initiated a
phase II preoperative study, the TECHNO trial, with epiru-
bicin/cyclophosphamide followed by paclitaxel/trastuzumab
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TECHNO TRIAL
Paclitaxel
175 mg/m²  q3w
Epirubicin 90 mg/m²
Cyclo. 600 mg/m² q3w
Herceptin
6 mg/kg q3w
OP
HER2/neu 3+ oder 2+ (FISH pos.)
phase II study
Herceptin
36 weeks
6 mg/kg q3w
 
Fig. 1. TECHNO Trial, design.
followed by postoperative therapy with trastuzumab in pa-
tients with HER2/neu-overexpressing primary breast cancer
(fig. 1). So far, histopathological reports of surgery after
chemotherapy and trastuzumab are available from 174 pa-
tients. According to the definition of the NSABP, 72 patients
(41.4%) have a histopathological complete remission. In
127/174 (73%) of the patients, axillary nodes are histologically
free of metastases at surgery.
The trastuzumab clinical trial program and the post-market-
ing surveillance demonstrated that trastuzumab is well toler-
ated, both when used as a single agent and in combination
with chemotherapy. The most common side effects observed
in clinical trials were mild to moderate infusion-related fever
and chills that occurred mostly in the first few hours of the
first infusion (25–40% incidence) [10, 13], with a trend to-
ward increased incidence at higher doses [10]. The clinically
most significant trastuzumab-associated adverse events were
serious infusion-related reactions and cardiotoxicity (espe-
cially in combination therapy with anthracyclines plus cy-
clophosphamide). The observed cardiac dysfunction has in-
fluenced the design of subsequent trials. Most studies request
formal baseline measurements of LVEF (LVEF ≥ 50% is usu-
ally required) before initiating treatment and have adopted
cardiac monitoring criteria [14]. The risk of cardiac failure as-
sociated with the use of trastuzumab can be justified by a sig-
nificant improvement of treatment outcome, time to progres-
sion and a longer median survival. The already overwhelming
results of the adjuvant trastuzumab trials mentioned above
indicate that we have an incredibly potent drug at hand.
However, it remains to be seen whether the long-term analy-
sis as well as analysis of all randomized patients will support
these promises.
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